reports
- Victor Floc’h
UPDATE SENSORION | Corporate, TP EUR6 |Game time for SENS-401
UPDATE SENSORION | Corporate, TP EUR6 |Game time for SENS-401 The most well-balanced equity story in hearing loss • Sensorion key investment highlights • SENS-401 in Sudden sensorineural hearing loss (SSNHL) • SENS-401 in Cisplatin-induced ototoxicity (CIO) • Inner ear is the next big thing in gene therapy • One of the broadest pipeline of inner ear gene tx • Valuation • We maintain our EUR6 TP
- Victor Floc’h
SENSORION - CORPORATE | EUR6(+217%) KOL Call Report: Cisplatin-induced...
SENSORION - CORPORATE | EUR6(+217%) KOL Call Report: Cisplatin-induced ototoxicity offers a promising opportunity for SENS-401 Dr. Schmitt highlighted the strong unmet medical need in this indication Chemotherapy’s lack of selectivity causes hearing loss A promising set of preclinical data supports SENS-401 in this indication CTA for NOTOXIS phase IIa trial should be submitted by year-end
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Dylan Van Haaften
- Jean-Jacques Le Fur
- Olga Smolentseva
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategi...
SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategic research collaboration A multi-year strategic collaboration A natural history study at the heart of this partnership A NHS provides critical information for rare and orphan diseases Once again confirms Sensorion’s leadership in hearing loss
- Victor Floc’h
THERANEXUS - CORPORATE | EUR20(+131%) BBDF-101 secures IND and moves i...
THERANEXUS - CORPORATE | EUR20(+131%) BBDF-101 secures IND and moves into clinic Phase III expected to start as soon as next year BBDF-101 is a perfect fit for Theranexus’ pipeline THN-102’s licensing deal remains an overhang for the equity story
- Victor Floc’h
SENSORION - CORPORATE | EUR6(+217%) Strong newsflow ahead, it’s time t...
SENSORION - CORPORATE | EUR6(+217%) Strong newsflow ahead, it’s time to jump in Several key catalysts expected in the short-term Sonova collaboration should be formerly signed in the near future The future of the Cochlear partnership should be announced soon SENS-401’s main inflexion point in sight Gene therapies are on track
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
- Victor Floc’h
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.